Type 1 phosphodiesterase Attention-deficit/hyperactivity disorder (ADHD) Fetal alcohol spectrum disorder (FASD) A B S T R A C T Pregnant smoking women are frequently episodic drinkers. Here, we investigated whether ethanol exposure restricted to the brain growth spurt period when combined with chronic developmental exposure to nicotine aggravates memory/learning deficits and hyperactivity, and associated cAMP and cGMP signaling disruption. To further investigate the role of these signaling cascades, we verified whether vinpocetine (a phosphodiesterase inhibitor) ameliorates the neurochemical and behavioral outcomes. Swiss mice had free access to nicotine (NIC, 50 mg/ml) or water to drink during gestation and until the 8th postnatal day (PN8). Ethanol (ETOH, 5 g/kg, i.p.) or saline were injected in the pups every other day from PN2 to PN8. At PN30, animals either received vinpocetine (20 mg/kg, i.p.) or vehicle before being tested in the step-down passive avoidance or open field. Memory/learning was impaired in NIC, ETOH and NIC + ETOH mice, and vinpocetine mitigated ETOH-and NIC + ETOH-induced deficits. Locomotor hyperactivity identified in ETOH and NIC + ETOH mice was ameliorated by vinpocetine. While cyclic nucleotides levels in cerebral cortex and hippocampus were reduced by NIC, ETOH and NIC + ETOH, this outcome was more consistent in the latter group. As observed for behavior, vinpocetine normalized NIC + ETOH nucleotides levels. pCREB levels were also increased in response to vinpocetine, with stronger effects in the NIC + ETOH group. Exposure to both drugs of abuse worsens behavioral and neurochemical disruption. These findings and the amelioration of deleterious effects by vinpocetine support the idea that cAMP and cGMP signaling contribute to nicotine-and ethanol-induced hyperactivity and memory/ learning deficits.
Introduction
Despite the known deleterious effects of tobacco smoke and alcoholic beverages on the offspring's health, both smoking and alcohol drinking prevalence during pregnancy have not changed substantially over the last 2 decades (CDC, 2009; Tong et al., 2013) . Indeed, 8.5-14.5% of women smoke during gestation (Curtin and Matthews, 2016; Mendelsohn et al., 2014; Tong et al., 2013) , whereas the prevalence of alcoholic beverages consumption is 13-20% (Balachova et al., 2012; CDC, 2009 ). These numbers may be even higher during breastfeeding (Tong et al., 2013; Tran et al., 2015) . As a result, maternal smoking and consumption of alcoholic beverages remain common preventable causes of infant morbidity (Abbott and Winzer-Serhan, 2012; Marquardt and Brigman, 2016) . Of particular relevance to the present study, epidemiological studies indicate that there is a strong association between smoking and alcohol drinking. Indeed, pregnant smoking women are frequently also episodic drinkers (Leonardson and Loudenburg, 2003; Walker et al., 2011) .
It is established that either ethanol or nicotine developmental exposure are neurotoxic and neuroteratogenic (Abbott and Winzer-Serhan, 2012; Marquardt and Brigman, 2016) . Early exposure to alcohol is associated with a multitude of long-term adverse effects, which are collectively named under the umbrella term Fetal Alcohol Spectrum Disorder (Lange et al., 2017; Riley et al., 2011) . Ethanol influences the function of various ligandgated ion channels, including nicotinic acetylcholine receptors, glycine, N-methyl-D-aspartate and serotonergic type 3 receptors (Larsson and Engel, 2004; Spanagel, 2009) . Smoking during pregnancy and breastfeeding also evokes a variety of harmful outcomes in the offspring (Abbott and Winzer-Serhan, 2012) . The deleterious effects of smoking are, at least in part, due to nicotine actions on nicotinic acetylcholine receptors as well as to the increase in the release of neurotransmitters, such as serotonin, dopamine, glutamate and gamma-aminobutyric acid, in several brain regions in response to nicotine administration (Wonnacott, 1997) .
Among the detrimental effects of maternal consumption of each of these drugs, increased risk of Attention Deficit Hyperactivity Disorder (ADHD) and memory/learning deficits stand out (England et al., 2017; Marquardt and Brigman, 2016; Weissenberger et al., 2017) . This is particularly worrisome since the shared detrimental effects of these drugs could lead to worsened outcomes in the offspring, expressed as either a higher frequency of occurrence or an increase in the severity of the observed deficits. There is evidence that the manifestation of hyperactivity and memory/learning deficits is associated with impairments in the second messenger cAMP and cGMP signaling pathways (Kleppisch, 2009; Manel Ben et al., 2016; Paine et al., 2009; Wang and Peng, 2016) . In these pathways (Medina, 2010) , the activation of adenylyl cyclase and guanylyl cyclase catalyzes the production of cAMP and cGMP respectively. cAMP activates cAMP-dependent protein kinase A (PKA), while cGMP activates Ras/Raf either directly or through the cGMP-dependent protein kinase G (PKG). Ultimately, both pathways lead to the phosphorylation of transcription factors such as CREB (cAMP response element binding protein) (Medina, 2010) , which, in turn, leads to the expression of genes that modulate neuronal excitability and plasticity within brain regions such as the frontal cortex and the hippocampus (Goto and Grace, 2007; Gurden et al., 1999) . Interestingly, exposure to either ethanol (Krahe et al., 2009; Kumada et al., 2010; Nunes et al., 2011) or nicotine (Brunzell et al., 2003; Radek et al., 2006; Vieyra-Reyes et al., 2008; Woo et al., 2002) disrupts cAMP/CREB and cGMP/CREB signaling in several brain regions, which characterizes these pathways as common molecular targets and suggests that their disruption is a shared mechanism of action of these drugs of abuse. In this sense, the possibility that exposure to one drug aggravates the behavioral and neurochemical outcomes evoked by the other is high (Abreu-Villaça et al., 2017) .
The intracellular levels of cAMP and cGMP are determined by the balance between their synthesis, which is regulated by cyclases, and their breakdown, which is regulated by phosphodiesterases (Bollen and Prickaerts, 2012) . The inhibition of the phosphodiesterase type 1 (PDE1) by vinpocetine prevents the breakdown of cyclic nucleotides cAMP and cGMP to their 5 0 -monophosphates, modulating the activation of transcription factors (Krahe et al., 2009; Medina, 2011) . Interestingly, acute vinpocetine treatment has been successfully used to mitigate both locomotor hyperactivity and memory/learning deficits (Filgueiras et al., 2010) in rodents exposed to ethanol during the neonatal period. However, little is known about the effects of vinpocetine on nicotine-induced deleterious outcomes, as well as on the basic neurobiology of the dual exposure to nicotine and ethanol during development.
Considering that: 1) pregnant smoking women may also be intermittent consumers of alcoholic beverages, 2) locomotor hyperactivity and memory/learning deficits observed in rodents early exposed to nicotine or to ethanol are associated with impairments in the cAMP and cGMP signaling cascades, 3) exposure to both nicotine and ethanol may lead to worsened outcomes when compared to exposure to either drug on its own, 4) vinpocetine was suggested as a therapeutic agent capable of mitigating the effects of early exposure to ethanol; here, we investigated the possibility that even a short-term intermittent exposure to ethanol, limited to the neonatal period, which, in rodents, roughly corresponds to the third trimester of human gestation, aggravates cAMP/CREB and cGMP/CREB signaling pathways disruption, and associated behavioral deficits in adolescent mice chronically exposed to nicotine during the period equivalent to the entire human gestation. To further investigate the role of these signaling cascades, we verified whether the inhibition of PDE1 by vinpocetine ameliorates the neurochemical and behavioral outcomes evoked by the drugs of abuse.
The nicotine concentration used in the drinking solution (Abreu-Villaça et al., 2007; Abreu-Villaca et al., 2007; RibeiroCarvalho et al., 2009; Ribeiro-Carvalho et al., 2011) generates cotinine (nicotine metabolite) plasma levels of 122-133 ng/ml (Ribeiro-Carvalho et al., 2009 ) that are close to those found in women that report smoking 10 (3-18) cigarettes/day during pregnancy (% 100 ng cotinine/ml) (Mamsen et al., 2017) . The ethanol dose was chosen based on previous studies (Filgueiras et al., 2010; Nunes et al., 2011) , which have shown that it generates blood ethanol concentrations of 239-316 mg/dL, within the range that a human fetus would be exposed to after maternal ingestion of a heavy dose of ethanol (>200 mg/dL). This level of exposure corresponds to what is estimated to be achieved in women who give birth to infants with negative outcomes of exposure including growth suppression and behavioral deficits (Driscoll et al., 1990) . The period of exposure to nicotine intended to parallel human exposure during gestation. In this regard, the prenatal development of rodents roughly corresponds to the first two trimesters of human pregnancy, while the third trimester equivalent of human gestation comprises the first 10-day period of postnatal life in mice and rats, a period called brain growth spurt (Clancy et al., 2007; Quinn, 2005) . Nicotine not only interferes with critical developmental events that occur during gestation, such as neurogenesis and early synaptogenesis, but also with dendritic arborization, late synaptogenesis and migration of multiple neuronal populations, which occur in great intensity during the first 10 days following birth (Bandeira et al., 2009; Dobbing and Sands, 1979; Dwyer et al., 2008) . Despite evidence that most women stop drinking when they verify that they are pregnant, a common pattern of maternal alcohol consumption is abstinence during the first two trimesters of pregnancy followed by consumption during the third trimester (Ethen et al., 2009) . Given this epidemiological finding and the fact that even a short period of intermittent exposure to ethanol during this stage of development has significant deleterious effects, here, ethanol exposure was restricted to the third trimester equivalent of human gestation. Ethanol exposure during this period was previously shown to induce cell loss and reduced neurogenesis (Gil-Mohapel et al., 2010; Olney et al., 2002) and to evoke detrimental effects such as locomotor hyperactivity and memory/ learning deficits in animal models (Filgueiras et al., 2010; Nunes et al., 2011; Thomas et al., 2001) . Exposure on alternate days was chosen to mimic episodic binge drinking. As for vinpocetine, the dose administered here was successfully used to mitigate hyperactivity and memory/learning deficits evoked by developmental ethanol (Filgueiras et al., 2010; Nunes et al., 2011) .
Materials and methods
This study was conducted under institutional approval of the Universidade do Estado do Rio de Janeiro (protocol#: CEUA/026/ 2012). All experiments were carried out in compliance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. Subjects were Swiss mice that were bred and maintained in our animal facility on a 12:12h light/dark cycle (lights on: 2:00 a.m., lights off: 2:00 p.m.) at a controlled temperature (22 AE 1 C). Access to food and water was unrestricted.
Animal treatment
Female mice were caged with male mice at the proportion of 2:1. After mating, each female was placed in an individual cage with free access to water and food until delivery. Dams were exposed to nicotine free base (50 mg/ml) dissolved in saccharin 2% (NIC) or to saccharin 2% in the drinking water (the sole source of fluid) during the whole gestation. After delivery, NIC dams continued to be exposed to nicotine until the 8th day of lactation. Ethanol (ETOH, 5 g/kg, i.p., 25%, v/v) or saline were injected in the pups every other day from postnatal day 2 (PN2) to PN8. Accordingly, each litter was assigned to one of the following groups: CONT (15 litters), ETOH (14 litters) NIC (11 litters), and NIC + ETOH (10 litters). The fluid consumption of the dams was measured every day while offspring body mass was measured every other day from lactation day (LD) 2 to 8.
At weaning (PN21) animals were separated by sex and housed in groups of 2-5 per cage. At the beginning of the adolescence period (PN30) (Spear, 2013) , the animals were randomly assigned, within each litter, to receive a single injection of vinpocetine (VP) 20 mg/kg (i.p., in dimethyl sulfoxide, DMSO, 0.5%, w/v), or an equivalent volume of DMSO.
As detailed below, after the injection, the animals were submitted to either the step-down passive avoidance or to the open field test (detailed below). Injections were carried out 4 h before the open field test and 1 h before the 1st passive avoidance session. These intervals were chosen because we aimed to test the animals in the open field and to allow the memory processes to take place during the period of vinpocetine-induced increase in cAMP and cGMP levels in mice, which extends approximately from 30 min to 6 h after its injection (unpublished data). Furthermore, we have previously demonstrated that within this time-interval, vinpocetine improves learning/memory deficits (Filgueiras et al., 2010) and reduces locomotor hyperactivity in rodents early exposed to ethanol.
Step-down passive avoidance test
The test apparatus contained one chamber (25 cm Â 25 cm Â 25 cm). Mice (n = 6-11 per group and sex) were submitted to three sessions: At PN30, 1 h after a single vinpocetine or DMSO injection, subjects were submitted to a training/ acquisition session (T0). Mice were placed in a circular platform (diameter = 6.5 cm) and allowed up to 3 min to descend from it, whereupon they received a mild foot shock (0.3 mA/3 s). Six (T6) and twenty-four (T24) hours later, the animals were retested. In each retesting session (T6 and T24), animals were allowed up to 3 min to descend from the platform (shock was not administered) (Abreu-Villaça et al., 2013b) . The 6-h intersession interval between T0 and T6 was chosen based on evidence that the memory consolidation processes modeled in the passive avoidance test are mediated by the activation of cAMP (2-6 h), cGMP (0-2 h) and pCREB (3-6 h), that occur during the first 6 h after T0 (Izquierdo et al., 2006) . All T0 and T24 sessions were performed between 8:00 a.m. and 8:30 a.m., while T6 sessions were performed between 2:00 p.m. and 2:30 p.m. At the end of each session, the floor was cleaned with ethanol 40%. The latency to step down from the platform in each testing session was noted. The learning/memory component of the passive avoidance task is expressed as an increase in the time spent in the platform from the 1st (T0) to the 2nd (T6) and/or 3rd (T24) sessions. At the end of all sessions, the floor was washed with odorless liquid soap, rinsed and dried.
Open field test
The open field arena consisted of a polypropylene box (37.6 cm Â 30.4 cm Â 17 cm) in which the floor was divided into 16 same-sized rectangles (7.6 cm Â 9.4 cm), 12 peripheral and 4 central. The experiments were conducted between 2:00 p.m. and 3:30 p.m. At PN30, 4 h after a single vinpocetine or DMSO injection, each mouse was individually placed in the center of the arena (n = 6-11 per group and sex). Behaviors in the open field were recorded for 10 min with an overhead video camera. At the end of the session, the floor and walls were cleaned with ethanol 40%. Recorded images of the tests were used to analyze behavior. Ambulation was quantified on the basis of the number of rectangles crossed by the animals . Mice had to place all four legs on a given rectangle for a crossing to be counted. The percentage of locomotor activity in the center, assessed as the number of rectangles crossed in the center corrected by the total ambulation, was used as a measure of anxiety-like behavior. In order to avoid contaminating the assessment of locomotor activity with the anxiety-associated locomotor behavior (Carola et al., 2002) , the number of rectangles crossed in the periphery was considered the measure of locomotor activity.
After the open field test, mice were killed by cervical dislocation. The cerebral cortices and hippocampi were immediately dissected, snap-frozen in liquid nitrogen and stored at À76 C.
cAMP and cGMP enzyme immunoassay
Hippocampi and right cortices (n = 4-8 per group and sex) intracellular cAMP and cGMP levels were determined using BIOTRAK cAMP (non-acetilation protocol) and cGMP (acetilation protocol) enzyme immunoassay kits respectively. The brain tissues were homogenized (3 times, 2370 Â g/20 s, 4 C) in a buffer that contained Tris HCl 0.1 M, 1 nM EDTA) and a phosphodiesterase inhibitor [1 mM 3-isobutyl-1-methylxanthine (IBMX)]. Ethanol was added to a final concentration of 65% and the homogenates were centrifuged at 1000 Â g for 2 min at 4 C. The supernatants were then transferred into a dry bath at 80 C. From this step onwards, the samples were manipulated according to the manufacturer's instructions. cAMP and cGMP data are expressed in fmol/mg tissue.
pCREB western blotting
Mice left cortices (n = 5-6 per group and sex) were homogenized (12,280 Â g /25 min, 4 C) in cell lysis buffer (50 mM HEPES, 1 mM MgCl2, 10 mM EDTA, and 1% Triton X-100, pH 6.4) with a protease inhibitor cocktail. Protein concentrations were measured using a BCA protein assay kit with bovine serum albumin as a standard. Next, samples were denatured in sample buffer (50 mM Tris HCl, pH 6.8, 1% SDS, 5% 2-mercaptoethanol, 10% glycerol, and 0.001% bromophenol blue) and heated at 95 C for 5 min. Homogenates were analyzed by the SDS-PAGE method. To detect the protein, we used a 12% polyacrylamide gel and 10 mg of total protein in each slot of the gel, and electroblotted using a nitrocellulose membrane. Membranes were incubated with Tween-TBS (20 mM Tris HCl, pH 7.5, 500 mM NaCl, 0.1% Tween-20) containing 5% of non-fat milk for 40 min to block nonspecific binding sites. Next, membranes were washed with Tween-TBS and incubated overnight at 5 C with anti-pCREB primary antibody (rabbit, 1:1000). Then, membranes were washed and incubated with the goat anti-rabbit secondary antibody conjugated to biotin (1:10,000) for 1 h at room temperature. Membranes were washed and incubated for 1 h at room temperature with streptavidin horseradish peroxidase (HRP) in the same dilution of the secondary antibody. The targeted protein was detected by chemiluminescence with the aid of the Image Quant (LAS 500, GE Healthcare, Little Chalfont, United Kingdom) apparatus. Finally, the area and density of the protein bands were quantified by Image J 1.34 s software (Wayne Rasband NIH, Boston, MA, USA).
Materials
Sigma Chemical Co. (St. Louis, MO, USA) was the source for nicotine free base, bovine albumin and anti-pCREB primary and secondary antibodies. BCA protein assay kit came from Thermo Scientific (Rockford, Illinois, USA). cAMP and cGMP EIA kits came from GE Healthcare UK Limited (Buckinghamshire, UK). Nitrocellulose membranes (Hybond-P ECL membrane) were provided by Amersham Pharmacia Biotech (NJ, USA). Roche Diagnostics (Indianapolis, IN, USA) was the source of the protease inhibitor cocktail, HR came from Millipore (Temecula, CA, USA) and the chemiluminescence kit was provided by ECL-plus; Amersham Pharmacia Biotech (Piscataway, NJ, USA). VETEC Química Fina Ltda (Rio de Janeiro, RJ, Brazil) was the source for all other reagents.
Statistical analyses
To reduce the likelihood of type 1 statistical errors that might result from repeated testing, results on each variable were evaluated first by global analysis of variance (ANOVAs) or repeated measures analyses of variance (rANOVA). ANOVAs were performed for body mass at PN30, locomotor activity, anxiety-like behavior, cAMP, cGMP and pCREB levels. rANOVAs were performed for the analyses of early postnatal body mass gain and dams' fluid intake (within-subject factor: Day), as well as of memory/learning performance (within-subject factor: Session). Exposure (CONT, ETOH, NIC, and NIC + ETOH), Treatment (DMSO and VP) and Sex were between-subject factors.
With this one-dimensional design (from now on described as 1-d), in which just one factor accounts for all groups of exposure, whenever significant Treatment effects or interactions were detected, lower-order ANOVAs on each treatment (DMSO and VP) were carried out. In these lower-order ANOVAs, all other factors were maintained in the analysis. Fisher's Protected Least Significant Difference (FPLSD) posthoc tests were used to investigate which groups were affected by the drugs of abuse (pairwise comparisons between DMSO groups). In addition, pairwise comparisons to investigate the impact of vinpocetine treatment were only used in instances that were biologically relevant (such as NIC DMSO Â NIC VP but not NIC DMSO Â ETOH VP ). To further verify whether vinpocetine restored behavior and neurochemical values to control levels, differences between CONT DMSO and VP groups and were evaluated posthoc by Dunnett tests.
In order to assess the possibility that nicotine and ethanol interacted, resulting in effects that were either more-than-additive (synergistic) or less-than-additive, a two-dimensional ANOVA design was used (from now on described as 2-d) (Abreu-Villaça et al., 2013a; Abreu-Villaça et al., 2013b; Abreu-Villaça et al., 2007; Ribeiro-Carvalho et al., 2009) . In this design, Ethanol (exposed: ETOH and NIC + ETOH; non-exposed: CONT and NIC) and Nicotine (exposed: NIC and NIC + ETOH; non-exposed: CONT and ETOH) are used as two independent between-factors in the analyses. Morethan-additive and less-than-additive effects are indicated by significant p-values regarding Nicotine Â Ethanol interactions in the ANOVAs. The distinction between more-and less-thanadditive effects is provided by the comparison of the effect observed for the NIC + ETOH group with the summation of the effects observed for the NIC and ETOH groups. In a twodimensional ANOVA, an additive effect is indicated by a nonsignificant p-value associated with Nicotine Â Ethanol interaction. As a result of the implementation of the two-dimensional design, the ANOVAs were comprised of three between-subjects factors: Nicotine (exposed or non-exposed), Ethanol (exposed or nonexposed), and Sex.
Data are compiled as means and standard errors of the means. Data from males and females of the same litter were averaged separately within each exposure/treatment group to minimize litter effects and avoid over-sampling (Wainwright, 1998) . There was no impact of the Sex factor on the results; therefore, male and female data are shown collapsed in the figures. Effects were considered significant when p < 0.05 (two-tailed).
Results

Body mass and dams fluid intake
Both dams' fluid intake (Day: F(6270) = 11.38, p < 0.001; LD2 = 24 AE 1.3 ml, LD8 = 36 AE 1.4 ml) and offspring's body mass (Day:
F(3,138) = 1565.6, p < 0.001; PN2 = 2.2 AE 0.04 g, PN8 = 5.0 AE 0.09 g) increased throughout the first week of the lactation period (data not shown). There were no differences between experimental groups (Table 1) .
At PN30, as expected, the mean litter body mass of males (25.5 AE 0.6 g) was significantly higher than that of females (23.1 AE 0.4 g) (Sex: F(1,139) = 12.3, p < 0.001). The 1-d ANOVA (Exposure: F(3,139) = 3.4, p = 0.02) indicated that the early exposure to the drugs of abuse influenced mean litter mass. Mice exposed to ETOH were lighter than control animals (p = 0.002, FPLSD) (Table 1 ). In addition, nicotine exposure prevented this ethanol-induced effect on body mass, as indicated by the lessthan-additive effect of Nicotine and Ethanol detected in the twodimensional design (Ethanol Â Nicotine: F(1, 139) = 4.73, p = 0.03). Nicotine alone did not affect body mass.
Step-down passive avoidance test
The 1d-rANOVA on T0, T6, and T24 measures indicated that the latency to leave the platform increased significantly from the first to the subsequent sessions (Session: F(1.8,222.3) = 55.0, p < 0.001), and that these increases in time were affected by the early exposure to the drugs of abuse and the acute treatment with vinpocetine (Exposure: F(3,122) = 3.6, p = 0.02; Treatment: F (1,122) = 11.5, p < 0.001; Session Â Exposure: F(5.5,222.3) = 3.1, p = 0.008; Session Â Treatment: F(1.8,222.3) = 4.0, p = 0.02). Accordingly, lower-order analyses on each session and treatment were conducted. There were no significant effects at T0. At T6, the lower-order 1-d analysis (Exposure: F(3,67) = 5.3, p = 0.03) indicated that the CONT DMSO group was significantly more efficient in the learning/ memory task than all other DMSO groups (CONT DMSO > ETOH DMSO : p = 0.002; CONT DMSO > NIC DMSO : p = 0.001; CON-T DMSO > NIC + ETOH DMSO : p = 0.004, FPLSD) (Fig. 1a) . While both nicotine and ethanol exposures evoked deficits, the impairment evoked by the dual exposure was smaller than the summation of the two individual sets of effects, reflecting a less-than additive outcome (2-d ANOVA -Ethanol Â Nicotine: F(1,67) = 5.6, p = 0.02). The acute treatment of mice with vinpocetine ameliorated the deficits, as evidenced by the fact that both ETOH VP and NIC + ETOH VP groups had higher latencies to leave the platform than their respective controls (ETOH DMSO < ETOH VP : p = 0.04; NIC + ETOH DMSO < NIC + ETOH VP : p = 0.04, FPLSD) (Fig. 1a) . A trend toward significance was also identified for the NIC groups (NIC DMSO < NIC VP : p = 0.08, FPLSD). The restoration of memory/ learning was further demonstrated by the lack of difference between the vinpocetine-treated mice and the CONT DMSO group (CONT DMSO = ETOH VP and NIC + ETOH VP , Dunnett).
At T24, as demonstrated by the lower-order 1-d analysis (Exposure: F(3,67) = 2.7, p = 0.05), CONT DMSO mice was more efficient in the learning/memory task than both ETOH DMSO (p = 0.01, FPLSD) and NIC + ETOH DMSO (p = 0.04, FPLSD) mice, however, there were no effects for the NIC group (Fig. 1b) . These results, together with the lack of an Ethanol Â Nicotine interaction in the 2-d ANOVA, connoted the fact that nicotine exposure did not alter the effects of ethanol. The mitigation of the deficits due to the vinpocetine treatment was evident by the significant higher latency to leave the platform identified in the ETOH VP vs. ETOH DMSO groups (p = 0.04, FPLSD) and by the close-to-significant increase identified in the NIC + ETOH DMSO vs. NIC + ETOH VP ones (p = 0.07, FPLSD) (Fig. 1b) . Furthermore, the performance of the vinpocetinetreated mice indicates that memory/learning was restored to control levels (CONT DMSO = ETOH VP and NIC + ETOH VP , Dunnett).
Open field test
The higher-order 1-d ANOVA indicated that both the early exposure to the drugs of abuse (F(3,134) = 4.3, p = 0.006) and the subsequent treatment with vinpocetine (F(1,134) = 10.1, p = 0.002) interfered with locomotor activity in adolescent mice. Lower-order analyses (1-d ANOVAs separated by Treatment) indicated that, in DMSO animals (Exposure: F(3,66) = 4.2, p = 0.01), both ETOH (p = 0.03) and NIC + ETOH (p = 0.001) mice were hyperactive when compared to CONT ones (Fig. 2) . Using the 2-d design, the ANOVA showed that the effect of the dual exposure reflected the summation of the effects of ethanol and nicotine (lack of Ethanol Â Nicotine interaction). Vinpocetine administration reduced locomotor activity levels as indicated by the amelioration of the hyperactive phenotype in ETOH VP (vs. ETOH DMSO , p = 0.03) and NIC + ETOH VP (vs. NIC + ETOH DMSO , p = 0.007, FPLSD) groups (Fig. 2) . In fact, the reduction of rectangles crossings was enough to bring activity down to control levels (CONT DMSO = ETOH VP and NIC + ETOH VP , Dunnett).
There were no significant effects of the drugs of abuse or vinpocetine treatment on anxiety-like behavior (data not shown).
cAMP levels
In the cerebral cortex, the 1-d ANOVA indicated that both the drugs of abuse and the acute treatment with vinpocetine affected cAMP levels (Treatment: F(1,79) = 7.0, p = 0.01; Exposure Â Treatment Â Sex: F(3,79) = 3.0, p = 0.04). Lower-order analyses (1-d ANOVAs separated by Treatment) demonstrated that, in DMSO animals (Exposure: F(3,38) = 3.3, p = 0.03), there was a reduction in cAMP levels in ETOH DMSO (p = 0.009, FPLSD), NIC (p = 0.04, FPLSD), and NIC + ETOH DMSO (p = 0.007, FPLSD) groups when compared to the CONT DMSO one (Fig. 3a) . These effects were similar in males and females (no Sex effects or interactions). The decrease in cAMP values identified in the NIC + ETOH group was indistinguishable from a simple summation of the effects of ethanol and nicotine (lack of Ethanol Â Nicotine interaction in the 2-d design). Vinpocetine administration restored cAMP levels in NIC + ETOH VP Fig. 1 . Memory/learning assessed in the step down passive avoidance test at PN30-31. Mice were exposed to: nicotine (NIC), during gestation and until the 8th postnatal day (PN8); ethanol (ETOH), every other day from PN2 to PN8; both drugs (NIC + ETOH); vehicle (CONT) and were treated with vinpocetine (VP) or DMSO at PN30. (a) Latency to step down in the second session (T6). (b) Latency to step down on the third session (T24). The dashed horizontal line represents the average of the latency to step down for controls in the training/acquisition session (T0) and the shaded area AE SEM. Values are means AE SEM. *p < 0.05, **p < 0.01, significant differences between drugs of abuse exposure groups. # p < 0.05, significant differences between treatment groups. Differences revealed by FPLSD. mice, in which cAMP levels were significantly higher than those observed in the NIC + ETOH DMSO group (p = 0.006, FPLSD), while they did not differ from those identified in control mice (CONT DMSO = NIC + ETOH VP ; Dunnett) (Fig. 3a) .
In the hippocampus, while the early exposure to the drugs of abuse reduced cAMP levels (1-d ANOVA, Exposure: F(3,82) = 8.9, p < 0.001), acute vinpocetine administration failed to affect the outcome. Therefore, lower-order analyses separated by Treatment (VP and DMSO) were not justified. cAMP levels were reduced in ETOH, NIC and NIC + ETOH mice when compared to CONT ones (for all comparisons, p < 0.001, FPLSD) (Fig. 3b) . Using the 2-d design, the ANOVA showed a significant Ethanol Â Nicotine interaction (F(1,38) = 4.9, p = 0.03) indicative of a less-than-additive effect of the dual exposure.
cGMP levels
In the cerebral cortex, the higher-order 1-d ANOVA indicated that the early exposure to the drugs of abuse had a major role in the reduction of cGMP levels (Exposure: F(3,82) = 4.7, p = 0.005), and that, inversely, the acute administration of mice with vinpocetine had a positive impact on cGMP levels (Treatment: F(1,82) = 13.7, p < 0.001). Lower-order analyses (1-d ANOVAs separated by Treatment) indicated that, in DMSO animals (Exposure: F (3,39) = 4.7, p = 0.008), cGMP levels were reduced in NIC and NIC + ETOH mice (CONT DMSO > NIC DMSO : p = 0.001; CON-T DMSO > NIC + ETOH DMSO : p = 0.008, FPLSD) (Fig. 4a) . The reduction in cGMP levels identified in the NIC + ETOH group was indistinguishable from a simple summation of the effects of ethanol and nicotine (lack of Ethanol Â Nicotine interaction in the 2-d design). Regarding the impact of vinpocetine, even though the decrease in cGMP evoked by ethanol exposure did not reach significance, there was an increase in its levels in response to vinpocetine administration (ETOH DMSO < ETOH VP : p < 0.001, FPLSD) (Fig. 4a) . As for the dual exposure, vinpocetine administration restored cGMP levels: NIC + ETOH VP ones were significantly higher than those observed in the NIC + ETOH DMSO group (p = 0.02, FPLSD), while they did not differ from those identified in CONT DMSO mice (CONT DMSO = ETOH VP and NIC + ETOH VP , Dunnett).
In the hippocampus, again, the drugs of abuse and the subsequent treatment with vinpocetine affected cGMP levels (1-d ANOVA -Exposure: F(3,60) = 3.4, p = 0.03; Exposure Â Treatment: F(3,60) = 3.5, p = 0.02). Lower-order analyses (1-d ANOVAs separated by Treatment) indicated that, in DMSO mice (Exposure: F(3,28) = 6.3, p = 0.003), there was a near significant reduction in cGMP levels in adolescent mice early-exposed to nicotine (CONT DMSO > NIC DMSO : p = 0.053, FPLSD), an effect that was intensified by the dual exposure, as evidenced by the marked difference between CONT DMSO and NIC + ETOH DMSO mice (p < 0.001, FPLSD) (Fig. 4b) as well as by the additive effect of nicotine and ethanol exposures (lack of Ethanol Â Nicotine interaction in the 2-d design). Vinpocetine administration, in turn, restored cGMP levels. NIC + ETOH mice that were treated with vinpocetine had increased cGMP levels when compared to mice from its respective control group (NIC + ETOH DMSO < NIC + ETOH VP : p = 0.002, FPLSD) (Fig. 4b) . In addition, NIC + ETOH VP cGMP values were undistinguishable from those identified in CONT DMSO mice (Dunnett).
pCREB levels
Vinpocetine acute administration had a major impact in cortical pCREB levels (1-d ANOVA -Treatment: F(1,90) = 11.9, p < 0.001), Fig. 3 . cAMP levels assessed in the cerebral cortex (a) and hippocampus (b) at PN30. Mice were exposed to: nicotine (NIC), during gestation and until the 8th postnatal day (PN8); ethanol (ETOH), every other day from PN2 to PN8; both drugs (NIC + ETOH); vehicle (CONT) and were treated with vinpocetine (VP) or DMSO at PN30. Values are means AE SEM. *p < 0.05, **p < 0.01, ***p < 0.001, significant differences between drugs of abuse exposure groups. ## p < 0.01, significant differences between treatment groups. Differences revealed by FPLSD. Fig. 4 . cGMP levels assessed in the cerebral cortex (a) and hippocampus (b) at PN30. Mice were exposed to: nicotine (NIC), during gestation and until the 8th postnatal day (PN8); ethanol (ETOH), every other day from PN2 to PN8; both drugs (NIC + ETOH); vehicle (CONT) and were treated with vinpocetine (VP) or DMSO at PN30. Values are means AE SEM. **p < 0.01, ***p < 0.001, significant differences between drugs of abuse exposure groups. connoting increased levels of CREB phosphorylation. Interestingly, pairwise comparisons indicated that the vinpocetine-evoked increase in pCREB levels only reached significance in mice exposed to both nicotine and ethanol (NIC + ETOH DMSO < NIC + ETOH VP mice: p = 0.02, FPLSD) (Fig. 5 ). There were no significant effects of early-exposure to the drugs of abuse.
Discussion
Here we show that exposure to ethanol and nicotine during development impaired behavioral and neurochemical measures long after the end of exposure, during early adolescence. However, while, for some measures, the effects were drug-dependent, either reflecting lingering outcomes of ethanol (locomotor activity and long-term memory/learning) or nicotine (cGMP levels), exposure to both nicotine and ethanol effectively disrupted most measures (memory/learning, locomotor activity, cortical and hippocampal cAMP and cGMP). It should be mentioned, however, that although the number of measures in which impairments occur increased due to the dual exposure when compared to the exposure to each drug separately, it does not necessarily follow that their severity is increased. Indeed, while the dual exposure evoked worsened outcomes for locomotor activity, cortical cAMP and cortical and hippocampal cGMP levels, reflecting the summation of individual effects of ethanol and nicotine, for memory/learning and hippocampal cAMP levels, the outcomes, despite significant, reflected less-than additive effects. We also show that vinpocetine treatment effectively ameliorated the behavioral deficits and restored neurochemical shortfalls evoked by nicotine and ethanol, which provides evidence for the potential therapeutic use of this PDE1 inhibitor. Of note, the effects of vinpocetine were more consistently identified in the group exposed to both ethanol and nicotine.
Exposure to either ethanol or nicotine
Ethanol exposure elicited memory/learning deficits at both time points (6 and 24 h) after the training session, which is in line with evidence that early postnatal exposure to this drug is capable of hampering memory consolidation (Filgueiras et al., 2010; Richardson et al., 2002) . As for nicotine, our results seem to corroborate previous findings of impaired memory/learning in rodents exposed to this drug during prenatal and early postnatal life (Balsevich et al., 2014; Yanai et al., 1992) . The deficits induced by nicotine were significant 6 h after the first session, but were no longer evident at 24 h. This result suggests that, as compared to ethanol, the memory deficits induced by nicotine were less severe.
While ethanol exposure during the brain growth spurt increased locomotor activity, corroborating previous findings (Melcer et al., 1994; Nunes et al., 2011) , there were no significant effects of nicotine. Even though previous studies report locomotor hyperactivity in rodents exposed to nicotine during gestation (Schneider et al., 2012; Zhu et al., 2012) , subtle and/or inconsistent effects were also described and may be attributed to distinct doses, routes and duration of exposure used in different studies (Heath et al., 2010) .
Previous findings suggest that reductions in cAMP and cGMP levels in brain regions such as the cerebral cortex and hippocampus are linked to hyperactivity and memory/learning deficits in rodents early-exposed to ethanol and nicotine (Kleppisch, 2009; Manel Ben et al., 2016; Paine et al., 2009; Wang and Peng, 2016) . Here, we observed that the cAMP and cGMP shortfalls were accompanied by cognitive impairment. In this regard, both hyperactivity and memory/learning deficits in ethanol-exposed mice were associated with reduced cAMP levels in the cerebral cortex and hippocampus. Distinctively, reduced cAMP levels in the hippocampus and cerebral cortex and reduced cGMP, mainly in the cerebral cortex, accompanied the nicotine-evoked deficits in memory/learning.
The dissimilar effects of nicotine and ethanol are likely explained by a combination of factors. Firstly, even though both drugs are known to disrupt cAMP and cGMP signaling cascades (Brunzell et al., 2003; Krahe et al., 2009; Kumada et al., 2010; Nunes et al., 2011; Radek et al., 2006; Vieyra-Reyes et al., 2008; Woo et al., 2002) , each drug acts through distinct receptors, which probably results in drug-specific patterns of interference in the cascades. Ethanol directly modulates the function of several inotropic receptors, enhancing the function at gamma-aminobutyric acid and glycine receptors, acting as a co-agonist at serotonergic and nicotinic acetylcholine receptors, and as a functional antagonist at glutamate N-methyl-D-aspartate receptors (Larsson and Engel, 2004; Spanagel, 2009) . Distinctively, nicotine primary site of action is the nicotinic acetylcholine receptor, with secondary effects on the function of other receptors (e.g. dopamine, serotonin, glutamate and gamma-aminobutyric acid) (Wonnacott, 1997) . Secondly, the cerebral cortex and hippocampus follow distinct developmental plans (Rodier, 1988) and express region-specific levels of the receptors targeted by each drug (e.g. Luján et al., 2005) , which might reverberate and interfere, through drug-specific pathways, eliciting region-dependent neurochemical alterations. Accordingly, we understand that the role of each neurotransmitter system and the integration of their effects, at synaptic and cell-signaling levels, may explain differences in results between drugs of abuse and brain regions.
Nicotine and ethanol exposure
Few studies compared the outcomes of nicotine and ethanol dual exposure during early development to those of nicotine or ethanol when administered separately. So far, co-exposure during gestation was shown to result in a more severe immune suppression (Basta et al., 2000) and enhanced acquisition of nicotine self-administration (Matta and Elberger, 2007) in the rat offspring. To the best of our knowledge, while detrimental behavioral effects of early exposure either to nicotine or to ethanol were described before (England et al., 2017; Marquardt and Brigman, 2016; Weissenberger et al., 2017) , this is the first time that lingering memory/learning deficits and hyperactivity in response to a chronic developmental exposure to nicotine when combined with an intermittent ethanol exposure restricted to the brain growth spurt period were demonstrated. In the present study, memory/learningdeficits in response to both drugs of abuse were smaller than the summation of nicotine and ethanol individual exposure effects. Despite that, the dual exposure to nicotine and ethanol still led to a poorer cognitive performance when compared to control mice. Regarding locomotor activity, mice exposed to both drugs of abuse were hyperactive, revealing an additive effect of the dual exposure. These data indicate that the severity in the outcomes of the dual exposure was behaviorspecific, which is in accordance with evidence that distinct cellular and molecular processes are responsible for each behavior (Izquierdo et al., 2006; Viggiano, 2008) .
To our knowledge, this is also the first study that describes the effects of nicotine and ethanol dual exposure on cAMP and cGMP levels. Interestingly, the reductions were evident for both cyclic nucleotides and in both brain regions. The effects on cGMP and cortical cAMP mostly reflected the summation of nicotine and ethanol individual effects. Besides, even when there were lessthan-additive effects, as identified for hippocampal cAMP, the magnitude of the reduction was similar to that evoked by each drug separately. These results imply that the impairment evoked by the dual exposure may be worse than the effect of each drug, and, if not, it is at least equivalent to the damage caused by either drug of abuse. Taken together, the current set of results evidencing that mice exposed to both nicotine and ethanol consistently exhibited hyperactivity and memory/learning deficits, as well as cAMP and cGMP shortfalls, is consistent with the idea that the cAMP and cGMP signaling system impairments underlie the drugs of abuse-induced behavioral deficits.
Vinpocetine ameliorates nicotine-and ethanol-induced behavioral and neurochemical deficits
The inhibition of PDE1 by vinpocetine was already shown to facilitate LTP (Molnár and Gaál, 1992) and ameliorate memory retrieval in rats (DeNoble, 1987) , and to improve cognition in patients with mild to moderate dementia (Hindmarch et al., 1991) . In rodents exposed to ethanol during the third trimester equivalent of human gestation, vinpocetine restores neuronal plasticity deficits in the visual cortex , ameliorates visuospatial memory/learning (Filgueiras et al., 2010) and locomotor hyperactivity . Here we show that vinpocetine mitigated most drugs of abuse-induced behavioral deficits and restored cAMP and cGMP levels in the cerebral cortex and hippocampus; brain regions rich in PDE1 (Lugnier, 2006) and that are involved in both locomotor activity and memory/learning deficits (Izquierdo et al., 2006; Viggiano, 2008) . Accordingly, the positive effects of the acute treatment with vinpocetine provide further evidence that impairments in cAMP and cGMP signaling cascades contribute to the behavioral deficits identified in mice exposed to ethanol and nicotine. Of note, we show that these beneficial effects are consistently identified in mice exposed to both drugs of abuse during development. Confirming that the vinpocetine treatment had significant effects downstream from the cyclic nucleotides, pCREB levels were increased in response to its administration, with stronger effects in the NIC + ETOH group. The vinpocetine-mediated increase in pCREB levels is in line with previous findings (Medina, 2011) , and may lead to the expression of genes that modulate neuronal excitability and plasticity (Goto and Grace, 2007; Gurden et al., 1999) . It should be noted that other transcription factors [e.g. the serum response factor (SRF) and the ETS transcription factor (ELK-1)] phosphorylation are also modulated by this PDE1 inhibitor (Medina, 2011) and by ethanol (Pandey et al., 2008) and nicotine (Kedmi and Orr-Urtreger, 2007) , which raises the possibility that other factors contribute to the link between cAMP and cGMP cascades and the behavioral outcomes of nicotine and ethanol exposure. Besides, vinpocetine has other actions that may take part in its therapeutic effects. In this regard, vinpocetine anti-inflammatory actions (Jeon et al., 2010; Medina, 2010) may counteract ethanol (Flores-Bastías and Karahanian, 2018; Pascual et al., 2017) and nicotine pro-inflammatory responses (Barr et al., 2007; Motaghinejad et al., 2017) , which have been associated with the deleterious behavioral outcomes of these drugs of abuse.
Our current work raises an interesting issue, which is whether the positive effects of a single injection of vinpocetine are long lasting or if continued treatment with this PDE1 inhibitor is necessary to consolidate the improved behavioral and neurochemical outcomes observed here. This point will be addressed in subsequent studies. In any case, notwithstanding the fact that we have shown that vinpocetine attenuates the deleterious effects of developmental exposure to ethanol and nicotine, possibly through its actions on the cyclic nucleotides, the fact that the dual ethanol and nicotine exposure might increase the odds and the severity of deleterious effects when compared to the outcomes of exposure to either drug on its own should nonetheless constitute a sobering reminder that the best way to avoid serious long-term health problems is to abstain from consumption of these drugs of abuse during gestation and lactation.
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